





Organ transplant recipients are at high risk of posttrans-
plantation lymphoproliferative disorders (PTLD) because of
immunosuppression and chronic immune stimulation by
both the grafted organ and possible viral infections such as
that by Epstein Barr virus (EBV). Plasma cell tumors are
rare, constituting 4% of all lymphomas observed in trans-
plant recipients [1-3]. We report the onset of a primary cuta-
neous plasmacytoma (PCP) in a dialysis patient. The tumor
was detected 1 year after chronic graft rejection.
2. Case Report
A 50-year-old white man developed chronic renal failure
due to focal segmental glomerulosclerosis. In 1986 he began
hemodialysis. In 1995 he underwent coronary artery bypass
surgery after acute myocardial infarction. In January 1998
the patient received a cadaveric renal transplant and there-
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after was maintained on immunosuppressive treatment
(cyclosporine 225 mg 3 times a day, mycophenolate mofetil
500 mg 3 times a day, and methylprednisolone 16 mg once a
day). Two episodes of acute rejection were treated with
steroids. At discharge from the transplantation center, the
patient’s serum creatinine concentration was 300 mol/L
(3.3 mg/dL).
In November 1998, mycophenolate mofetil was replaced
by azathioprine because of gastrointestinal discomfort attrib-
uted to the former drug. In January 1999 the serum creati-
nine concentration was 425 mol/L (4.8 mg/dL).
In December 2000 the patient was admitted to the
nephrology department because of chronic graft rejection
with fluid overload and heart failure. The serum creatinine
concentration was 665 mol/L (7.5 mg/dL). A few days after
the admission, all the immunosuppressive drugs were
stopped. Hemodialysis was restarted.
In August 2001 surgical nephrectomy was performed. In
September 2001 and in February 2002 the patient underwent
percutaneous transluminal coronary angioplasty. In March
2002 he presented at the Department of Dermatology with
an erythematous plaque 10 cm in diameter on the right leg
(Figure 1). The lesion was not painful. The patient reported
that the lesion had developed on his leg 1 year earlier and
had grown slowly. He denied any previous trauma or insect
bite at the site. A physician had prescribed oral antibiotics
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Figure 1. A, Skin lesions on the lower part of the right leg. B, Detail of
the skin lesions on the lower part of the right leg.
Figure 2. A, Diffuse plasma cell infiltrate (hematoxylin and eosin, orig-
inal magnification 2). B, Atypical plasma cells with hyperchromic and
binucleate nuclei (hematoxylin and eosin, original magnification 20). C,
Plasma cells with light chain  positivity (immunohistocytochemical, orig-
inal magnification 20).
with no benefit. The patient had not sought any other med-
ical advice.
Skin biopsy revealed a dense, nodular infiltrate of
mononuclear cells within the superficial and intermediate
layers of the dermis. Cytomorphologic examination showed
predominance of plasma cells with B- and T-lymphocytes.
Immunohistologic examination demonstrated monoclonal
expression of immunoglobulin  light chains by the plasma
cells (Figure 2). Anti–latent membrane protein monoclo-
nal autoantibodies (Dako, Glostrup, Denmark) were used
in a search for EBV in tumor cells, and the results were
negative [4].
The diagnostic work-up included a full blood cell count,
serum electrophoresis, serum and urine immunofixation,
bone marrow biopsy, total body computed tomographic scan,
and bone scintigraphy.All findings were within normal limits.
The T-cell panel was normal.The results for immunoglobulin
G (IgG) against EBV capsid and nuclear antigens were pos-
itive, but those for IgM were negative.
In August 2002 the patient underwent local radiotherapy
and had a complete response. At the time of this writing, the
patient was alive and well with no signs of cutaneous or sys-
temic involvement.
3. Discussion
Malignant plasma cell tumors present in several forms,
ranging from small localized lesions to widely disseminated
disease. Localized forms include solitary plasmacytoma of
the bone and extramedullary plasmacytoma, which are con-
sidered separate entities with different clinicopathological
and prognostic features. Both forms can evolve into systemic
disease. Lesions arising primarily in the skin are rare [5-8].
PCP is a rare disease described for the first time in 1949
[8]. Since then approximately 32 cases have been reported.
PCP predominantly affects elderly or middle-aged men
(mean age, 60 years; male to female ratio, 4:1). Clinically
there may be as many as 50 cutaneous reddish to purple nod-
ules, nodes, and plaques with no predilection for a particular
site [5-7]. Ulceration of the lesions is rare. Because of the
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paucity of the cases for which long-term follow-up informa-
tion is available, the course of the disease and its prognosis
are difficult to evaluate. Disease progression with systemic
involvement has been reported in 7 of 14 patients with more
than 3 years of follow-up [8]. Four of 14 achieved complete
remission, and the others had local recurrences. As for prog-
nostic factors, some authors [5-8] differentiate solitary and
multiple forms of the disease, the latter apparently having a
more aggressive course with higher mortality. Clinicopatho-
logical findings, such as IgA secretion by neoplastic cells, may
be indicative of a more aggressive course [8].
Cancer is a well-known complication of solid organ trans-
plantation. Furthermore, a multicenter study demonstrated
that the incidence of cancer among patients receiving dialy-
sis for end-stage renal disease is higher than that in the gen-
eral population [9,10].
The incidence of lymphoma among transplant recipients
is 20 times higher than in an age- and sex-matched control
population [1,2]. Much confusion has arisen about the
nomenclature of the majority of the lesions; consequently,
the nonspecific term PTLD has been widely accepted [3,11].
This term covers a very wide spectrum of disorders ranging
from benign hyperplasia at one end to frankly malignant
lymphoma at the other. Of the 1931 cases of PTLD in the
Cincinnati Transplant Tumor registry that were studied
immunologically, 86% were of B-cell origin, 14% were of
T-cell origin, and rare cases were null cell origin or were com-
bined B- and T-cell lymphoma [1]. Myeloma/plasmacytoma
accounted for only 4% of all the cases [12,13].The reason for
the low incidence of this malignancy in comparison with that
of lymphoma is poorly understood [14].
Multiple risk factors for PTLD have been reported:
aggressive immunosuppression with more than 2 or 3 drugs
and the use of antilymphocyte globulin or muromonab-CD3
(OKT3). Heart and lung transplant recipients who need
aggressive treatment of acute rejection have a higher risk
[15-17]. More than 90% of patients with PTLD have positive
results for EBV. Plasmacytoma may follow reactivation of
EBV infection after transplantation [18,19].
Plasmacytoma in transplant recipients may affect bones,
the oral cavity, the skull, the abdomen and, in a few cases, the
skin [20,21]. There are few data on the prognosis and survival
of patients with posttransplantation plasmacytoma. Plasmacy-
toma occurring within the first year after transplantation gen-
erally presents as localized disease and is associated with a
significantly lower mortality rate. It usually responds favorably
to a decrease in immunosuppressive therapy and to chemo-
therapy. In contrast, the mortality among patients developing
late plasmacytoma is as high as 80%. This late form is fre-
quently disseminated disease and sometimes does not
respond to a reduction of immunosuppressive therapy [22-25].
These differences may reflect a continuous transition
from benign B-cell hyperplasia in response to EBV infection
to oligoclonal or monoclonal proliferation. Given the small
number of reported cases, the role of immunosuppression in
the etiology of posttransplantation myeloma has not been
clearly established. Immunosuppressive therapy may be
reduced or discontinued in renal allograft recipients, and
such patients have a better prognosis than nonrenal allograft
recipients [22-25].
Possible therapeutic strategies for plasmacytoma include
local radiotherapy, chemotherapy alone or with autologous
peripheral blood stem cell transplantation or hematopoietic
stem cell transplantation [26-35].
Malignant plasma cells are extremely sensitive to radia-
tion [26]. A solitary extramedullary plasmacytoma can be
successfully irradiated. Radiation also can be used to treat
symptomatic lesions, to stabilize bones at risk of fracture, and
to treat spinal cord compression. Patients often benefit from
the expertise of an orthopedic surgeon skilled in cancer man-
agement, because prophylactic fixation of impending patho-
logical fractures is occasionally warranted.
Several chemotherapeutic agents are used to treat multi-
ple myeloma. The regimen most often used is melphalan and
prednisone (M and P) orally administered for 4 to 7 days.The
cycle is repeated every 4 to 6 weeks, depending on recovery
of blood cell counts. Patients tolerate this therapy extremely
well but, rarely, report nausea or fatigue. The overall
response rate is approximately 50%.
Although many other combinations of chemotherapy (eg,
vincristine, bischloroethylnitrosourea [BCNU], melphalan,
cyclophosphamide, and prednisone [VBMCP]; vincristine,
adriamycin, and dexamethasone [VAD]; and VBMCP/vin-
cristine, BCNU, adriamycin, and prednisone [VBAP]) exist,
in 2 metaanalyses investigators compared M and P with com-
bination chemotherapy and found no significant advantage
in response percentage, response duration, or survival rates
with combination chemotherapy [27,28]. Bisphosphonates
are used to promote bone healing and to provide secondary
prophylaxis against skeletal events (eg, bone fracture and
spinal cord compression) [29].
Only a few cases of bone marrow transplantation (BMT)
for hematologic neoplasia after solid organ transplantation
have been reported in the literature. Possible reasons are that
the patients were too ill to tolerate high-dose chemotherapy
and the presence of graft-versus-host disease (GVHD),
major organ toxicity, and infections. Furthermore, the risk of
organ rejection after BMT cannot be ignored [30-34].
Autologous peripheral blood stem cell transplantation
was performed in a kidney transplant recipient affected by
multiple myeloma.After 2 years of follow-up the patient was
alive and well, and no recurrences of the myeloma had been
detected. Peripheral stem cell grafts contain approximately
10 times more T- and-B cells than do marrow grafts. Because
these cells may survive for a long time in transplant recipi-
ents, patients who receive such grafts may be less immuno-
compromised than recipients of marrow. Immune reconstitu-
tion seems to be faster with a peripheral source of stem cells
than with BMT. CD3 counts are reconstituted to normal lev-
els 2 to 4 months after transplantation, whereas CD4 may
remain at low levels for at least the first year [30].
A case of disseminated EBV-related plasmacytoma [35],
which occurred in a renal allograft recipient 13 years after
transplantation, has been described. The patient’s son had
donated the kidney. Nonmyeloablative hematopoietic stem
cell transplantation with peripheral blood from the kidney
donor was performed. With the onset of GVHD, the
myeloma resolved. A subsequent isolated relapse occurred
in the central nervous system, ultimately leading to the
patient’s death.
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In conclusion, our patient may be of interest because his
is the first case of PCP reported in a dialysis patient. The
patient presented with a solitary lesion on the right leg.
According to the patient, the lesion had appeared 2 years
after hemodialysis was restarted, approximately 1 year
before he sought medical advice. The lesion had grown
slowly. Despite the long delay between the onset of the first
lesion and the diagnosis, none of the investigations revealed
any systemic disease. The tumor responded well to radiation
therapy. After 2 years no recurrences had been found.
In light of our clinical experience and the data literature,
we suggest that dialysis patients undergo regular skin exam-
inations. Any suspicious lesion should be immediately
referred to a dermatology department for prompt diagnosis
and therapy.
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